Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis

ABSTRACT Pulmonary lesions from active tuberculosis patients are thought to contain persistent, nonreplicating bacilli that arise from hypoxic stress. Metronidazole, approved for anaerobic infections, has antituberculosis activity against anoxic bacilli in vitro and in some animal models and may target persistent, nonreplicating bacilli. In this double-blind, placebo-controlled trial, pulmonary multidrug-resistant tuberculosis subjects were randomly assigned to receive metronidazole (500 mg thrice daily) or placebo for 8 weeks in addition to an individualized background regimen. Outcomes were measured radiologically (change on high-resolution computed tomography [HRCT]), microbiologically (time to sputum smear and culture conversion), and clinically (status 6 months after stopping therapy). Enrollment was stopped early due to excessive peripheral neuropathies in the metronidazole arm. Among 35 randomized subjects, 31 (15 metronidazole, 16 placebo) were included in the modified intent-to-treat analysis. There were no significant differences by arm in improvement of HRCT lesions from baseline to 2 or 6 months. More subjects in the metronidazole arm converted their sputum smear (P = 0.04) and liquid culture (P = 0.04) to negative at 1 month, but these differences were lost by 2 months. Overall, 81% showed clinical success 6 months after stopping therapy, with no differences by arm. However, 8/16 (50%) of subjects in the metronidazole group and 2/17 (12%) of those in the placebo group developed peripheral neuropathy. Subjects who received metronidazole were 4.3-fold (95% confidence interval [CI], 1.1 to 17.1) more likely to develop peripheral neuropathies than subjects who received placebo. Metronidazole may have increased early sputum smear and culture conversion but was too neurotoxic to use over the longer term. Newer nitroimidazoles with both aerobic and anaerobic activity, now in clinical trials, may increase the sterilizing potency of future treatment regimens.

[1]  A. Diacon,et al.  Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824 , 2012, Antimicrobial Agents and Chemotherapy.

[2]  B. Robertson,et al.  Unusual features of the cell cycle in mycobacteria: polar-restricted growth and the snapping-model of cell division. , 2007, Tuberculosis.

[3]  E. Boesen,et al.  Indications for Hypophysectomy , 1962 .

[4]  B. Abomoelak,et al.  Induction of a Novel Class of Diacylglycerol Acyltransferases and Triacylglycerol Accumulation in Mycobacterium tuberculosis as It Goes into a Dormancy-Like State in Culture , 2004, Journal of bacteriology.

[5]  A. Coxon,et al.  METRONIDAZOLE NEUROPATHY , 1976, Journal of neurology, neurosurgery, and psychiatry.

[6]  S. Giosué,et al.  Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis. , 1999, American journal of respiratory and critical care medicine.

[7]  C. Sohaskey,et al.  Nonreplicating persistence of mycobacterium tuberculosis. , 2001, Annual review of microbiology.

[8]  K. Lamp,et al.  Pharmacokinetics and Pharmacodynamics of the Nitroimidazole Antimicrobials , 1999, Clinical pharmacokinetics.

[9]  A. Diacon,et al.  14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial , 2012, The Lancet.

[10]  H. Boshoff,et al.  Nitroimidazoles for the treatment of TB: past, present and future. , 2011, Future medicinal chemistry.

[11]  W. Bishai,et al.  Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency. , 2008, The Journal of infectious diseases.

[12]  G. Davies.  Early clinical development of anti-tuberculosis drugs: science, statistics and sterilizing activity. , 2010, Tuberculosis.

[13]  Sang-Nae Cho,et al.  Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. , 2010, Chest.

[14]  F. Giannoni,et al.  Activities of Drug Combinations against Mycobacterium tuberculosis Grown in Aerobic and Hypoxic Acidic Conditions , 2013, Antimicrobial Agents and Chemotherapy.

[15]  A. Kuriyama,et al.  Metronidazole-Induced Central Nervous System Toxicity: A Systematic Review , 2011, Clinical neuropharmacology.

[16]  S. Furney,et al.  Metronidazole Therapy in Mice Infected with Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[17]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[18]  Ya-Fang Chen,et al.  Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[19]  E. Boyce,et al.  Persistent Metronidazole-Induced Peripheral Neuropathy , 1990, DICP : the annals of pharmacotherapy.

[20]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[21]  J. Flynn,et al.  Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques , 2012, Proceedings of the National Academy of Sciences.

[22]  S. Kamat,et al.  Role of metronidazole in improving response and specific drug sensitivity in advanced pulmonary tuberculosis. , 1989, The Journal of the Association of Physicians of India.

[23]  M. D. Granado,et al.  WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update , 2011, European Respiratory Journal.

[24]  Stanley Lu,et al.  Cerebellar ataxia following prolonged use of metronidazole: case report and literature review. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[25]  D. Sharp,et al.  Reversible optic neuropathy due to metronidazole , 2007, Clinical & experimental ophthalmology.

[26]  K. Andries,et al.  Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[27]  James A. Raleigh,et al.  Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates , 2008, Infection and Immunity.

[28]  E. Uçan,et al.  High resolution computed tomographic findings in pulmonary tuberculosis. , 1996, Thorax.

[29]  C. Senner,et al.  Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.

[30]  S. Piscitelli,et al.  Clinical Pharmacokinetics of Metronidazole and Other Nitroimidazole Anti-Infectives , 1992, Clinical pharmacokinetics.

[31]  V. Leimane,et al.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis , 2012, European Respiratory Journal.